A method for treating a myeloproliferative disorder which is conventionally treated with hydroxyurea selected from the group consisting of granulocytic leukemia, polycythemia vera and essential thrombocytosis in a mammal, said method comprising administering to said mammal a therapeutic amount of hydroxyurea and a therapeutic amount of inhibitor of glutathione synthesis and/or depleter of glutathione selected from the group consisting of L-buthionine-S-sulfoximine, ethacrynic acid, L-prothionine-S-sulfoximine, L-pentathionine-S-sulfoximine, and diethylmaleate.